These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 2572403)
1. Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease. Lauritsen K Dan Med Bull; 1989 Sep; 36(4):378-93. PubMed ID: 2572403 [No Abstract] [Full Text] [Related]
2. [Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid]. Malchow H Internist (Berl); 1987 Jan; 28(1):14-20. PubMed ID: 2883152 [No Abstract] [Full Text] [Related]
3. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease. van Hees PA Acta Gastroenterol Belg; 1987; 50(5):555-9. PubMed ID: 2902723 [No Abstract] [Full Text] [Related]
4. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
5. [New developments in the treatment of inflammatory bowel diseases. What is certain?]. Feurle GE Z Gastroenterol Verh; 1990 Apr; 25():150-2. PubMed ID: 1694355 [No Abstract] [Full Text] [Related]
6. [Prevention of recurrence of chronic inflammatory bowel diseases]. Dölle W; Hartmann F Verh Dtsch Ges Inn Med; 1989; 95():322-6. PubMed ID: 2574922 [No Abstract] [Full Text] [Related]
7. [Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis]. Maier KP Dtsch Med Wochenschr; 1992 Oct; 117(42):1614-5. PubMed ID: 1356747 [No Abstract] [Full Text] [Related]
9. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303 [TBL] [Abstract][Full Text] [Related]
10. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid]. Feurle GE; Helmstädter V Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908 [No Abstract] [Full Text] [Related]
12. Sulfasalazine and new analogues. Friedman G Am J Gastroenterol; 1986 Feb; 81(2):141-4. PubMed ID: 2868653 [No Abstract] [Full Text] [Related]
13. Sulphasalazine in inflammatory bowel disease: recent advances. Cooper BT N Z Med J; 1986 Oct; 99(811):757-9. PubMed ID: 2877428 [No Abstract] [Full Text] [Related]
14. Sulfasalazine and 5-ASA compounds. Allgayer H Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468 [TBL] [Abstract][Full Text] [Related]
15. [Significance of free oxygen radicals for pathogenesis of chronic inflammatory disease]. Nielsen OH; Ahnfelt-Rønne I Ugeskr Laeger; 1992 Sep; 154(38):2544-6. PubMed ID: 1357806 [No Abstract] [Full Text] [Related]
17. [Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid]. Fahrländer H Schweiz Med Wochenschr; 1987 Oct; 117(42):1620-3. PubMed ID: 3321418 [TBL] [Abstract][Full Text] [Related]
18. [Aminosalicylates in the treatment of chronic inflammatory bowel diseases]. Hartmann F; Plauth M Internist (Berl); 1990 Nov; 31(11):702-6. PubMed ID: 2289856 [No Abstract] [Full Text] [Related]
20. Will there be a next generation of sulfasalazine? Goldman P Gastroenterology; 1982 Nov; 83(5):1138-41. PubMed ID: 6126420 [No Abstract] [Full Text] [Related] [Next] [New Search]